세계의 비강내 약물전달 기기 시장 : 시스템별, 용기별, 용도별 - 기회 분석과 산업 예측(2024-2033년)

Intranasal Drug Delivery Devices Market By System , By Container By Application : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,402,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,724,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

전 세계 비강내 약물전달 기기 시장 규모는 2023년에 17억 달러로 평가되며 2024년부터 2033년까지 연평균 8.7%의 CAGR로 성장하여 2033년에는 38억 달러에 달할 것으로 예상됩니다.

비강내 약물전달 기기는 비강을 통해 치료제를 투여하도록 설계된 의료기기입니다. 이 투여 경로는 소화관이나 간에서의 1차 통과 대사를 우회하여 약물을 전신 순환계로 직접 전달하거나 중추 신경계를 표적으로 삼을 수 있는 비침습적이고 효율적인 수단을 제공합니다. 비강내 장치에는 일반적으로 비강 스프레이, 분무기, 분말 디스펜서 등이 있으며, 비강 점막을 통한 약물 흡수를 증가시키도록 조정되어 있습니다.

세계 비강내 약물전달 기기 시장의 성장은 호흡기질환, 알레르기, 편두통, 간질 및 오피오이드 과다 복용과 같은 신속한 약물 작용이 필요한 질환의 놀라운 유병률 증가에 의해 주도되고 있습니다. 공중보건 연구기관인 Institute for Health Metrics and Evaluation의 조사에 따르면, 만성 호흡기질환은 2019년 4억 5,460만 건의 유병률로 4백만 명의 사망을 유발하여 사망 원인 중 3위를 차지하였습니다. 또한, 환자들 사이에서 비침습적 약물전달 방법에 대한 수요가 급증하고 있으며, 만성 및 급성 증상 모두에 대한 비강내 약물전달 기기의 채택을 촉진하고 있습니다. 또한, 비경구 약물전달은 약물이 혈액뇌장벽을 우회할 수 있기 때문에 중추신경계를 표적으로 삼는 데 효과적입니다. 이 때문에 알츠하이머병, 파킨슨병과 같은 신경계 질환의 치료 연구가 촉진되고 있습니다. 또한, 재택의료 및 셀프 메디케이션의 증가 추세는 비강 장치를 포함한 사용하기 쉬운 약물전달 시스템에 대한 수요를 촉진하고 있으며, 이는 시장 성장을 크게 촉진하고 있습니다. 그러나 비강내 장치의 빈번한 사용은 비강 점막에 자극, 건조 및 기타 불편함을 유발할 수 있기 때문에 채택이 제한되어 시장 성장을 저해하고 있습니다. 또한, 안정성 문제 및 비강 점막의 낮은 투과성으로 인해 모든 약물이 비강내 전달에 적합하지 않아 이러한 장치의 적용 범위가 제한됩니다. 반면, 정량적 비강 점적기나 바늘을 사용하지 않는 장치와 같은 기술 혁신은 약물전달의 정확성과 사용 편의성을 향상시키고 있습니다. 용량 추적용 센서와 통합된 스마트 장치도 등장하여 환자의 복약 순응도를 향상시키고 있습니다. 이러한 발전은 예측 기간 동안 세계 시장 확대에 유익한 기회를 제공할 것으로 예상됩니다.

비강내 약물전달 기기 산업은 시스템, 용기, 용도, 지역으로 구분됩니다. 시스템별로 시장은 정량투여 시스템, 다회투여 시스템, 단위투여 시스템으로 구분됩니다. 용기별로는 비가압 용기와 가압 용기로 구분됩니다. 용도별로는 만성폐쇄성폐질환(COPD), 비염, 낭포성섬유증, 코막힘, 천식, 기타로 구분됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 시장을 분석하고 있습니다.

주요 조사 결과

시스템별로는 2024-2033년 다회투여 시스템 부문이 시장을 장악할 것으로 예측됩니다.

용기별로는 비압축 시스템 용기 부문이 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

용도별로는 천식 부문이 가까운 시일 내에 눈에 띄는 속도로 성장할 것으로 예상됩니다.

지역별로는 북미가 2023년 비강내 약물전달 기기 시장에서 가장 큰 시장 점유율을 차지했으며, 예측 기간 동안에도 시장을 지배할 것으로 예상됩니다.

본 보고서에서 가능한 보고서 커스터마이징(추가 비용 및 일정에 대해서는 영업 담당자에게 문의)

• 고객의 관심사에 따른 기업 프로파일 추가
• 과거 시장 데이터
• 수출입 분석/데이터

목차

제1장 소개

제2장 주요 요약

제3장 시장 상황

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 비강내 약물전달 기기 시장 : 시스템별

• 시장 개요
• 정량 투여
• 다회 투여 시스템
• 단위 투여 시스템

제5장 비강내 약물전달 기기 시장 : 용기별

• 시장 개요
• 비가압 용기
• 가압 용기

제6장 비강내 약물전달 기기 시장 : 용도별

• 시장 개요
• 만성폐쇄성폐질환
• 비염
• 낭포성섬유증
• 코 막힘
• 천식
• 기타

제7장 비강내 약물전달 기기 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국의 비강내 약물전달 기기 시장
  • 캐나다의 비강내 약물전달 기기 시장
  • 멕시코의 비강내 약물전달 기기 시장
• 유럽
  • 주요 시장 동향과 기회
  • 프랑스의 비강내 약물전달 기기 시장
  • 독일의 비강내 약물전달 기기 시장
  • 이탈리아의 비강내 약물전달 기기 시장
  • 스페인의 비강내 약물전달 기기 시장
  • 영국의 비강내 약물전달 기기 시장
  • 기타 유럽의 비강내 약물전달 기기 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 중국의 비강내 약물전달 기기 시장
  • 일본의 비강내 약물전달 기기 시장
  • 인도의 비강내 약물전달 기기 시장
  • 한국의 비강내 약물전달 기기 시장
  • 호주의 비강내 약물전달 기기 시장
  • 기타 아시아태평양의 비강내 약물전달 기기 시장
• 라틴아메리카, 중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질의 비강내 약물전달 기기 시장
  • 남아프리카공화국의 비강내 약물전달 기기 시장
  • 사우디아라비아의 비강내 약물전달 기기 시장
  • 기타 라틴아메리카, 중동 및 아프리카 비강내 약물전달 기기 시장

제8장 경쟁 구도

• 소개
• 주요 성공 전략
• 주요 10개 기업 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝 : 2023년

제9장 기업 개요

• AptarGroup, Inc.
• Teleflex Incorporated
• Nemera
• Becton, Dickinson And Company
• OptiNose, Inc.
• GlaxoSmithKline Plc.
• AstraZeneca
• Kurve Technology, Inc.
• Johnson And Johnson
• Merck And Co., Inc.

ksm

영문 목차

영문목차

The intranasal drug delivery devices market was valued at $1.7 billion in 2023, and is projected to reach $3.8 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033.

Intranasal drug delivery devices are medical devices designed to administer therapeutic agents through the nasal cavity. This route of administration provides a non-invasive and efficient means to deliver drugs directly into the systemic circulation or target the central nervous system, bypassing the gastrointestinal tract and first-pass metabolism in the liver. Intranasal devices commonly include nasal sprays, nebulizers, and powder dispensers, tailored to enhance drug absorption through the nasal mucosa.

The growth of the global intranasal drug delivery devices market is driven by alarming increase in prevalence of respiratory diseases, allergies, migraines as well as conditions requiring rapid drug action, such as epilepsy and opioid overdose. According to a study published by the Institute for Health Metrics and Evaluation-a public health research institute-chronic respiratory diseases were responsible for 4.0 million deaths with a prevalence of 454.6 million cases in 2019, ranking as the third leading cause of death. In addition, surge in demand for non-invasive drug delivery methods among patients is boosting the adoption of intranasal devices for both chronic and acute conditions. Moreover, intranasal drug delivery is effective in targeting the central nervous system, as it allows drugs to bypass the blood-brain barrier. This is fostering research into treatments for neurological disorders, such as Alzheimer's and Parkinson's disease. Furthermore, rise of home healthcare and self-medication trends is driving the demand for easy-to-use drug delivery systems, including intranasal devices, which significantly fosters the market growth. However, frequent use of intranasal devices may cause irritation, dryness, or other discomfort in the nasal mucosa, which limits their adoption, thereby hampering the market growth. In addition, not all drugs are suitable for intranasal delivery due to stability issues or low permeability through the nasal mucosa, which restricts the range of applications for these devices. On the contrary, innovations such as metered-dose nasal sprays and needle-free devices improve drug delivery precision and user-friendliness. Smart devices integrated with sensors for dose tracking are also emerging, enhancing patient adherence. Such developments are expected to offer remunerative opportunities for the expansion of the global market during the forecast.

The intranasal drug delivery devices industry is segmented into system, container, application, and region. By system, the market is segregated into metered dose, multi-dose systems, and unit-dose systems. On the basis of containers, it is bifurcated into non-pressurized containers and pressurized containers. Depending on application, it is divided into chronic obstructive pulmonary disease (COPD) , rhinitis, cystic fibrosis, nasal congestion, asthma, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By system, the multi-dose systems segment is expected to dominate the market from 2024 to 2033.

On the basis of container, the non-pressurized system containers segment is anticipated to exhibit the highest growth during the forecast period.

Depending on application, the asthma segment is projected to grow at a notable pace in the near future.

Region wise, North America held the largest market share in the intranasal drug delivery devices market in 2023, and is expected to dominate the market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global intranasal drug delivery devices market include AptarGroup, Inc., Teleflex Incorporated, Nemera, Becton, Dickinson and Company, OptiNose, Inc., GlaxoSmithKline Plc., AstraZeneca, Kurve Technology, Inc., Johnson & Johnson, and Merck & Co., Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Additional company profiles with specific to client's interest
• Historic market data
• Import Export Analysis/Data

Key Market Segments

By System

• Metered Dose
• Multi-Dose Systems
• Unit-Dose Systems

By Container

• Non-Pressurized Containers
• Pressurized Containers

By Application

• Chronic Obstructive Pulmonary Disease
• Rhinitis
• Cystic Fibrosis
• Nasal Congestion
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players:

• AptarGroup, Inc.
• Teleflex Incorporated
• nemera
• Becton, Dickinson and Company
• OptiNose, Inc.
• GlaxoSmithKline plc.
• AstraZeneca
• Kurve Technology, Inc.
• Johnson & Johnson
• Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY SYSTEM

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By System
• 4.2. Metered Dose
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. Multi-Dose Systems
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country
• 4.4. Unit-Dose Systems
  • 4.4.1. Key Market Trends, Growth Factors and Opportunities
  • 4.4.2. Market Size and Forecast, By Region
  • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY CONTAINER

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Container
• 5.2. Non-Pressurized Containers
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Pressurized Containers
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY APPLICATION

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By Application
• 6.2. Chronic Obstructive Pulmonary Disease
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Rhinitis
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Cystic Fibrosis
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country
• 6.5. Nasal Congestion
  • 6.5.1. Key Market Trends, Growth Factors and Opportunities
  • 6.5.2. Market Size and Forecast, By Region
  • 6.5.3. Market Share Analysis, By Country
• 6.6. Others
  • 6.6.1. Key Market Trends, Growth Factors and Opportunities
  • 6.6.2. Market Size and Forecast, By Region
  • 6.6.3. Market Share Analysis, By Country

CHAPTER 7: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY REGION

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By Region
• 7.2. North America
  • 7.2.1. Key Market Trends and Opportunities
  • 7.2.2. Market Size and Forecast, By System
  • 7.2.3. Market Size and Forecast, By Container
  • 7.2.4. Market Size and Forecast, By Application
  • 7.2.5. Market Size and Forecast, By Country
  • 7.2.6. U.S. Intranasal Drug Delivery Devices Market
    • 7.2.6.1. Market Size and Forecast, By System
    • 7.2.6.2. Market Size and Forecast, By Container
    • 7.2.6.3. Market Size and Forecast, By Application
  • 7.2.7. Canada Intranasal Drug Delivery Devices Market
    • 7.2.7.1. Market Size and Forecast, By System
    • 7.2.7.2. Market Size and Forecast, By Container
    • 7.2.7.3. Market Size and Forecast, By Application
  • 7.2.8. Mexico Intranasal Drug Delivery Devices Market
    • 7.2.8.1. Market Size and Forecast, By System
    • 7.2.8.2. Market Size and Forecast, By Container
    • 7.2.8.3. Market Size and Forecast, By Application
• 7.3. Europe
  • 7.3.1. Key Market Trends and Opportunities
  • 7.3.2. Market Size and Forecast, By System
  • 7.3.3. Market Size and Forecast, By Container
  • 7.3.4. Market Size and Forecast, By Application
  • 7.3.5. Market Size and Forecast, By Country
  • 7.3.6. France Intranasal Drug Delivery Devices Market
    • 7.3.6.1. Market Size and Forecast, By System
    • 7.3.6.2. Market Size and Forecast, By Container
    • 7.3.6.3. Market Size and Forecast, By Application
  • 7.3.7. Germany Intranasal Drug Delivery Devices Market
    • 7.3.7.1. Market Size and Forecast, By System
    • 7.3.7.2. Market Size and Forecast, By Container
    • 7.3.7.3. Market Size and Forecast, By Application
  • 7.3.8. Italy Intranasal Drug Delivery Devices Market
    • 7.3.8.1. Market Size and Forecast, By System
    • 7.3.8.2. Market Size and Forecast, By Container
    • 7.3.8.3. Market Size and Forecast, By Application
  • 7.3.9. Spain Intranasal Drug Delivery Devices Market
    • 7.3.9.1. Market Size and Forecast, By System
    • 7.3.9.2. Market Size and Forecast, By Container
    • 7.3.9.3. Market Size and Forecast, By Application
  • 7.3.10. UK Intranasal Drug Delivery Devices Market
    • 7.3.10.1. Market Size and Forecast, By System
    • 7.3.10.2. Market Size and Forecast, By Container
    • 7.3.10.3. Market Size and Forecast, By Application
  • 7.3.11. Rest Of Europe Intranasal Drug Delivery Devices Market
    • 7.3.11.1. Market Size and Forecast, By System
    • 7.3.11.2. Market Size and Forecast, By Container
    • 7.3.11.3. Market Size and Forecast, By Application
• 7.4. Asia-Pacific
  • 7.4.1. Key Market Trends and Opportunities
  • 7.4.2. Market Size and Forecast, By System
  • 7.4.3. Market Size and Forecast, By Container
  • 7.4.4. Market Size and Forecast, By Application
  • 7.4.5. Market Size and Forecast, By Country
  • 7.4.6. China Intranasal Drug Delivery Devices Market
    • 7.4.6.1. Market Size and Forecast, By System
    • 7.4.6.2. Market Size and Forecast, By Container
    • 7.4.6.3. Market Size and Forecast, By Application
  • 7.4.7. Japan Intranasal Drug Delivery Devices Market
    • 7.4.7.1. Market Size and Forecast, By System
    • 7.4.7.2. Market Size and Forecast, By Container
    • 7.4.7.3. Market Size and Forecast, By Application
  • 7.4.8. India Intranasal Drug Delivery Devices Market
    • 7.4.8.1. Market Size and Forecast, By System
    • 7.4.8.2. Market Size and Forecast, By Container
    • 7.4.8.3. Market Size and Forecast, By Application
  • 7.4.9. South Korea Intranasal Drug Delivery Devices Market
    • 7.4.9.1. Market Size and Forecast, By System
    • 7.4.9.2. Market Size and Forecast, By Container
    • 7.4.9.3. Market Size and Forecast, By Application
  • 7.4.10. Australia Intranasal Drug Delivery Devices Market
    • 7.4.10.1. Market Size and Forecast, By System
    • 7.4.10.2. Market Size and Forecast, By Container
    • 7.4.10.3. Market Size and Forecast, By Application
  • 7.4.11. Rest of Asia-Pacific Intranasal Drug Delivery Devices Market
    • 7.4.11.1. Market Size and Forecast, By System
    • 7.4.11.2. Market Size and Forecast, By Container
    • 7.4.11.3. Market Size and Forecast, By Application
• 7.5. LAMEA
  • 7.5.1. Key Market Trends and Opportunities
  • 7.5.2. Market Size and Forecast, By System
  • 7.5.3. Market Size and Forecast, By Container
  • 7.5.4. Market Size and Forecast, By Application
  • 7.5.5. Market Size and Forecast, By Country
  • 7.5.6. Brazil Intranasal Drug Delivery Devices Market
    • 7.5.6.1. Market Size and Forecast, By System
    • 7.5.6.2. Market Size and Forecast, By Container
    • 7.5.6.3. Market Size and Forecast, By Application
  • 7.5.7. South Africa Intranasal Drug Delivery Devices Market
    • 7.5.7.1. Market Size and Forecast, By System
    • 7.5.7.2. Market Size and Forecast, By Container
    • 7.5.7.3. Market Size and Forecast, By Application
  • 7.5.8. Saudi Arabia Intranasal Drug Delivery Devices Market
    • 7.5.8.1. Market Size and Forecast, By System
    • 7.5.8.2. Market Size and Forecast, By Container
    • 7.5.8.3. Market Size and Forecast, By Application
  • 7.5.9. Rest of LAMEA Intranasal Drug Delivery Devices Market
    • 7.5.9.1. Market Size and Forecast, By System
    • 7.5.9.2. Market Size and Forecast, By Container
    • 7.5.9.3. Market Size and Forecast, By Application

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top Winning Strategies
• 8.3. Product Mapping Of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. AptarGroup, Inc.
  • 9.1.1. Company Overview
  • 9.1.2. Key Executives
  • 9.1.3. Company Snapshot
  • 9.1.4. Operating Business Segments
  • 9.1.5. Product Portfolio
  • 9.1.6. Business Performance
  • 9.1.7. Key Strategic Moves and Developments
• 9.2. Teleflex Incorporated
  • 9.2.1. Company Overview
  • 9.2.2. Key Executives
  • 9.2.3. Company Snapshot
  • 9.2.4. Operating Business Segments
  • 9.2.5. Product Portfolio
  • 9.2.6. Business Performance
  • 9.2.7. Key Strategic Moves and Developments
• 9.3. Nemera
  • 9.3.1. Company Overview
  • 9.3.2. Key Executives
  • 9.3.3. Company Snapshot
  • 9.3.4. Operating Business Segments
  • 9.3.5. Product Portfolio
  • 9.3.6. Business Performance
  • 9.3.7. Key Strategic Moves and Developments
• 9.4. Becton, Dickinson And Company
  • 9.4.1. Company Overview
  • 9.4.2. Key Executives
  • 9.4.3. Company Snapshot
  • 9.4.4. Operating Business Segments
  • 9.4.5. Product Portfolio
  • 9.4.6. Business Performance
  • 9.4.7. Key Strategic Moves and Developments
• 9.5. OptiNose, Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Key Executives
  • 9.5.3. Company Snapshot
  • 9.5.4. Operating Business Segments
  • 9.5.5. Product Portfolio
  • 9.5.6. Business Performance
  • 9.5.7. Key Strategic Moves and Developments
• 9.6. GlaxoSmithKline Plc.
  • 9.6.1. Company Overview
  • 9.6.2. Key Executives
  • 9.6.3. Company Snapshot
  • 9.6.4. Operating Business Segments
  • 9.6.5. Product Portfolio
  • 9.6.6. Business Performance
  • 9.6.7. Key Strategic Moves and Developments
• 9.7. AstraZeneca
  • 9.7.1. Company Overview
  • 9.7.2. Key Executives
  • 9.7.3. Company Snapshot
  • 9.7.4. Operating Business Segments
  • 9.7.5. Product Portfolio
  • 9.7.6. Business Performance
  • 9.7.7. Key Strategic Moves and Developments
• 9.8. Kurve Technology, Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Key Executives
  • 9.8.3. Company Snapshot
  • 9.8.4. Operating Business Segments
  • 9.8.5. Product Portfolio
  • 9.8.6. Business Performance
  • 9.8.7. Key Strategic Moves and Developments
• 9.9. Johnson And Johnson
  • 9.9.1. Company Overview
  • 9.9.2. Key Executives
  • 9.9.3. Company Snapshot
  • 9.9.4. Operating Business Segments
  • 9.9.5. Product Portfolio
  • 9.9.6. Business Performance
  • 9.9.7. Key Strategic Moves and Developments
• 9.10. Merck And Co., Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Key Executives
  • 9.10.3. Company Snapshot
  • 9.10.4. Operating Business Segments
  • 9.10.5. Product Portfolio
  • 9.10.6. Business Performance
  • 9.10.7. Key Strategic Moves and Developments

관련자료